Podoplanin, a small mucine-type transmembrane glycoprotein, has been recently shown to be expressed by lymphangiogenic, fibrogenic and mesenchymal progenitor cells in the acutely and chronically infarcted myocardium. Podoplanin binds to CLEC-2, a C-type lectinlike receptor 2 highly expressed by CD11b high cells following inflammatory stimuli. Why podoplanin expression appears only after organ injury is currently unknown. Here, we characterize the role of podoplanin in different stages of myocardial repair after infarction and propose a podoplanin-mediated mechanism in the resolution of post-MI inflammatory response and cardiac repair. Neutralization of podoplanin led to significant improvements in the left ventricular functions and scar composition in animals treated with podoplanin neutralizing antibody. The inhibition of the interaction between podoplanin and CLEC-2 expressing immune cells in the heart enhances the cardiac performance, regeneration and angiogenesis post MI. Our data indicates that modulating the interaction between podoplanin positive cells with the immune cells after myocardial infarction positively affects immune cell recruitment and may represent a novel therapeutic target to augment post-MI cardiac repair, regeneration and function. 
INTRODUCTION
The role of inflammation in the setting of myocardial infarction (MI) has been extensively studied and these observations generated significant enthusiasm regarding potential use of antiinflammatory strategies to reduce infarct size and to attenuate post-MI injury (1) . However, therapeutic approaches have not yet succeeded since impaired inflammatory cell recruitment that debride the wound, may negatively affect the scar formation and healing in the injured heart (2). Thus, new insights into understanding the post-MI modulation of inflammatory response is needed for the development of successful cardioprotective therapies. In this study, we investigated a novel cell-cell interaction of podoplanin positive cells to inflammatory cells in the modulation of post MI inflammation. Characterization of podoplanin expression after MI has recently been described suggesting podoplanin expression by heterogenous population of lymphangiogenic, fibrogenic and mesenchymal progenitor cells (3) .
Podoplanin is a mucin-like transmembrane glycoprotein that plays an important role in organ development, cell motility, tumorigenesis and metastasis (4) . Given its pleiotropic functions, podoplanin is expressed by a wide variety of cells (5) including lymphatic endothelial cells, podocytes, alveolar type I cells, tumor cells and cancer-associated fibroblasts (6) . Importantly, podoplanin appears in the infarcted heart as early as 2 days after MI (3) . Lately, it has been documented that interstitial stromal cells acquire podoplanin after organ injury (7) and under several pathological conditions such as fibrosis (8, 9) and autoimmune disease (10, 11) . The expression of podoplanin increases during inflammation in sepsis (12) and in animal models of deep vein thrombosis (13) and aortic calcification (14) . In the adult heart, podoplanin-positive cells are rare, constituting less than 5% of the myocardial small cell population (15) . In fact, in homeostatic conditions podoplanin is expressed only by cardiac lymphatic endothelial cells (3) . In fact, in homeostatic conditions podoplanin is expressed only by cardiac lymphatic endothelial cells (3) . Cardiac podoplanin expressing cells have been previously characterized by Cimini et al. (3) ; where they analyzed spatial and temporal distribution of the cells that acquire this glycoprotein after ischemic injury. Although podoplanin is a common lymphoendothelial marker, it is expressed with an unexpected heterogeneity and the appearance of podoplanin positive cells increases over time from the acute (2 days) to the chronic phase of the MI (2 weeks and one month) (3) . The interstitial podoplanin positive cells did not express LYVE-1, a specific lymphatic endothelial marker, Prox-1, a major transcription factor of the lymphatic endothelial fate and VEGFR-3 unless organized in cardiac lymphatic vessels (16) . This suggests that a large portion of podoplanin positive cells do not possess a differentiated lymphatic endothelial phenotype. Additionally, podoplanin positive cells do not express markers of mature endothelial cells like CD31 and VEGFR2 (17) . The immunohistochemistry and the flow cytometry analysis of the infarcted hearts at different time points after MI showed that the podoplanin positive cells were distinctly PDGFRα positive. The co-localization of PDGFRβ with podoplanin was infrequent early after MI and strongly elevated at later stages of infarct healing in the mature scar. Since PDGFRα is associated with the properties of immature mesenchymal cells and PDGFRβ is a marker of pericytes the concordance of co-staining with podoplanin suggested that podoplanin expressing cells contain also a population with progenitor capabilities. Of note, although PDGFRα and PDGFRβ are also associated with fibrogenic behavior, podoplanin positive cells do not express vimentin and α Smooth muscle actin at any time point, suggesting that podoplanin positive cells do not generate fully differentiated fibroblasts (3) . Podoplanin therefore may represent a sign of activation of a cohort of cells during different phases of postischemic myocardial wound repair.
Podoplanin binds to C-type lectin-like receptor 2 (CLEC-2) (18, 19) that is exclusively expressed by platelets and a variety of immune cells (20) . Interestingly, CLEC-2 is upregulated in CD11b high cells like monocytes and macrophages following inflammatory stimuli (21) . Under physiological conditions, podoplanin in normal tissues does not have access to CLEC-2 on inflammatory cells (21) ; however, during developmental stages (6, 20, 22) or under pathological conditions (4), they interact with each other and play various important physiological or pathophysiological roles (4) . Although the function of podoplanin in development (4, 6, 22) and tumor metastasis (23) is well documented, the role of podoplanin remains unclear in the repair of injured organs (7) and, in particular, in repair of ischemic heart (3) .
Here, we demonstrate that the neutralization of podoplanin using neutralizing antibodies, improved the heart function and the scar composition after MI. In particular, we show that the interaction of podoplanin positive cells with monocytes and macrophages alters inflammatory responses in the phase of granulation post MI and leads to cardiomyocyte survival and-or regeneration in the infarct region. Our data supports a novel and alternative mechanism of interactome in the heart that, when neutralized, leads to altered inflammatory response and preservation of cardiac function and structure. Collectively, our data indicates that the neutralization of podoplanin/CLEC-2 interaction after MI may represent a novel therapeutic strategy to augment post-MI cardiac repair and function.
RESULTS

Cardiac injury induces the expression of podoplanin
Podoplanin expression has been reported to increase from acute to chronic phase of MI (3). Analysis of podoplanin expression revealed that compared to sham operated hearts, where podoplanin was expressed only by lymphatic endothelial cells ( Figure 1A -B, labeled in red), post-MI hearts showed significantly augmented expression of podoplanin in the infarct border zone as early as 2-days post-MI ( Figure 1C-D, labeled in red) . Since different models of cardiac stress such as Angiotensin II, leads to cardiac fibrosis (24, 25) , we also investigated podoplanin expression in the post-angiotensin II infusion-induced cardiac fibrosis. The fibrotic areas (supplementary Fig S1A) were positive for podoplanin (supplementary Figures S1B-C, labeled in red) and negative for α Smooth muscle actin (supplementary Figure S1B , labeled in green), suggesting that podoplanin positive cells are distinct from activated myofibroblast and may play a distinct role in the regulation of fibrosis. Interestingly, podoplanin was also highly expressed in the fibrotic cardiac tissue samples of human ischemic cardiomyopathy patients ( Figure 1E and 1F, same area of interest, as well as supplementary Figure S1D and S1E), suggesting that enhanced podoplanin expression is not limited to failing murine hearts and that podoplanin expression increases in the fibrotic human diseased hearts.
To understand the biology of MI-induced podoplanin positive cells in detail, we isolated podoplanin positive cells from infarcted mouse hearts at 2 days after MI using magnetic beads and the cells were culture expanded in vitro (Figure 2A-B) . We verified the purity of the cultured cells by flow cytometry which showed highly enriched population with minimal contamination with LYVE-1 positive lymphatic endothelial cells ( Figure 2B ). To confirm the cardiac source of these cells and rule out bone marrow/circulation source, we additionally determined podoplanin expressing cells in the circulation of sham and post-MI mice. As shown by the scatter plots ( Figure 2C-D) , none of the bone marrow lineage-positive cells expressed podoplanin and this expression did not increase post MI suggesting that podoplanin-positive cells reside in the heart and are not recruited from the bone marrow. To test the hypothesis that podoplanin is a marker of injured myocardium and that blocking of podoplanin activity may lead to positive post-MI remodeling, we first tested neutralizing activity of anti-podoplanin antibodies to inhibit migration of podoplanin-positive cells under inflammatory conditions by in vitro migration assays. Podoplanin positive cells displayed an intense migratory capacity towards LPS-conditioned medium. This migration was inhibited by two independent podoplanin neutralizing antibodies (antibodies A and B, respectively), as shown in Figure 2E . Both antibodies showed similar inhibitory activity and were used for further in vitro and in vivo experiments.
Podoplanin neutralization improves cardiac function after myocardial infarction
We next tested whether podoplanin neutralization in vivo would enhance cardiac functions after MI. Mice were subjected to MI by permanent LAD ligation and were treated with intra-peritoneal injections of 25μg of neutralizing antibody, 25μg of isotype matched rabbit IgG or saline solution at 1, 2, 7 and 15 days after MI. Left ventricular (LV) functions were evaluated in all mice at baseline and on days 7 and 30 post-MI by echocardiographic measurements. These studies revealed that on day 7 post-MI, left ventricular LV Ejection Fraction (%EF) ( Figure 3A ) and Fractional Shortening (%FS) ( Figure 3B ) were significantly reduced in all the groups while LV diameters at end-diastole and -systole (LVEDD and LVESD) ( Figure 3C and 3D) were equally increased, suggesting comparative infarct in treated and controls (IgG and saline) groups. In contrast, 30 days after MI the echocardiography data showed that podoplanin neutralization significantly improved LV functions compared with both groups of control animals ( Figure 3 A-D). In addition to echocardiography, we also performed hemodynamic evaluations (Supplementary data, Figure S2 A-C). Animals treated with neutralizing antibody exhibited an improved LV contractility and relaxation in response to β-adrenergic stimulation with isoproterenol at 30 days after MI compared with the two groups of controls. Together these data demonstrated significantly improved post-MI cardiac functions in the animals treated with podoplanin neutralizing antibody and suggested that neutralization of podoplanin may be a new strategy for post-infarct structural and functional repair. Figure 4A , graph). To further confirm the cardio-protective activity of the podoplanin neutralizing antibody, we performed TUNEL assay on treated and saline control mouse hearts at 3 days after MI; podoplanin neutralization significantly reduced number of TUNEL positive cells (supplementary Figure S3B ). Scar tissue of treated animals displayed robust neovascularization of the healed tissue compared with control samples ( Figure 4B , CD31 labeled in red). Additionally, myofibroblast proliferation and the α Smooth muscle actin (αSMA) expression were strongly inhibited in treated animals ( Figure 4B , αSMA labeled in green) at 30 days after MI compared to control animals. The untreated animals were characterized by fibrotic scar expressing αSMA, and myofibroblasts were located lengthwise along the scar with fibronectin assemblies ( Figure   4C , fibronectin labeled in green) of the extracellular matrix (ECM). In contrast, in treated animals fibronectin was organized in structures similar to swirls ( Figure 4C , fibronectin labeled in green) which suggest further new vessel formation. Of note, new lymphangiogenesis ( Figure  4D , LYVE-1 labeled in red) was not inhibited by the anti podoplanin neutralizing antibody in the treated animals where regular new lymphatic vessel formation was observed ( Figure 4C ), confirming that the lymphatic endothelial cells do not represent an off target podoplanin expressing cell population.
Selective inhibition of podoplanin improves post-infarction remodeling
Podoplanin neutralization stimulates endogenous tissue regeneration after myocardial infarction
Neovascularization and organization of the scar fibrosis are important for the recruitment and proliferation of progenitor cells involved in tissue repair (26) . Differentiated cells could be derivative of resident progenitor cells in the tissue or recruited from the circulation; therefore, we investigated the presence of undifferentiated cells at the time of tissue granulation. Interestingly, we found significantly higher number of immature NKX 2.5 expressing cells in the infarcted tissue of treated animals compared to controls at 7 days post-MI ( Figure 5A , NKX 2.5 labeled in red). We further identified groups of small nucleated cells in niches that were double positive for NKX 2.5 and Troponin T ( Figure 5B , NKX 2.5 labeled in red and Troponin T labeled in green) suggesting these cells may represent undifferentiated cardiac progenitors that may potentially differentiate into the myocyte lineage. These double positive cells either in cluster ( Figure 5B) or as isolated single cells (supplementary Figure S4C ) were found dispersed within the scar or in multiple areas of the border zone of the ischemic tissue in all the heart samples of animals treated with podoplanin-neutralizing antibody (supplementary Figure S4B ). Few NKX 2.5 positive cells were also identified in the control animals ( Figure 5A and 5B); none of which were positive for Troponin T ( Figure 5B ). Interestingly, we documented organized groups of small myocytes within the scar tissue of animals treated with podoplanin-neutralizing antibody at 30 days after MI ( Figure 5C -E). The small myocytes were characterized by expression of α Sarcomeric actin (αSARC-labeled in green); expressed connexin 43 gap junction ( Figure 5C , connexin 43 labeled in red) and showed functional contractile proteins troponin T ( Figure 5D , troponin T labeled in red) and troponin I ( Figure 5E , troponin I labeled in red). The figures show consecutive section of the same area. Remote area of the same samples was used as an internal control (supplementary Figure S4E-4G ). These islands of small myocytes were rarely found in the scar of control animals. These intriguing data suggest that events downstream of podoplanin neutralization foster the progenitor cell survival likely by altering the scar microenvironment; therefore, we next investigated the interaction between podoplanin and CLEC-2-expressing cells and how this interaction may regulate inflammatory and proliferative phases of the inflammation, post MI.
Podoplanin neutralization alters inflammatory responses in injured myocardium
Based on the sequential migration of inflammatory cells after MI, we focused our attention on the monocyte/macrophage (27) populations as podoplanin-interacting cells since monocyte recruitment to heart follows a similar time frame as the appearance of podoplanin (1). As already described before (21), we first verified that podoplanin-positive cells (labeled in red) interact in vivo with CD68 ( Figure 6A , CD68 labeled in green) and CD163 positive ( Figure 6B , CD163 labeled in green) cells two days after MI using two complementary approaches of histological and flow cytometry analyses. The histological analysis of the immune infiltrate at 3 days after MI in the control and treated groups showed two different immunological landscapes. Monocytes positive for CD68 (labeled in green) and CD163 (labeled in red) were present in injured left ventricular area of both group of animals; in the control group monocyte infiltration was predominately composed of CD68 positive cells ( Figure 6C ) compared to the CD163 population ( Figure 6C , graph). However, animals treated with neutralizing antibody displayed a monocyte composition dominated by CD163 positive cells compared to the CD68 positive population ( Figure 6D ). Histological data were further confirmed by flow-cytometry analysis of mononuclear cells isolated by digestion of mice hearts of treated and untreated animals at 3 days after MI. The single cell suspension was stained for CD86, CD68, CD163, and CD206. The pan monocyte/macrophage marker CD86 showed a similar cell numbers between control and treated animals ( Figure 6E ). However, the monocyte/macrophage population resident in the hearts of animals treated with podoplanin neutralizing antibody was predominantly positive for CD163 ( Figure 6G ) and CD206 ( Figure 6H ) whereas in control group it was predominantly positive for CD68 ( Figure 6F ). These data indicate that there was a marked recruitment or in situ differentiation of anti-inflammatory monocytes/macrophages (CD163/CD206) in the infarcted myocardium of animals treated with podoplanin neutralizing antibody; therefore, we next assessed cytokine and chemokine expression patterns to characterize the bio-signals following the neutralization of podoplanin-binding monocytes.
To investigate whether neutralization of podoplanin positive cell binding to monocytes may lead to monocyte/macrophage phenotype switch, we isolated primary bone marrow monocytes from C57BL/6 wild type mice and activated them in vitro in the presence of lipopolysaccharide (LPS). Compared to naïve monocytes, activated monocytes displayed increased population of CD68 expressing cells as verified by flow cytometry ( Figure 7B ). LPS-activated monocytes were negative for CD163 ( Figure 7C ). Since LPS stimulated monocytes mimic in vivo activated and recruited monocyte population, we co-cultured podoplanin positive cells with activated monocytes with and without the presence of podoplanin neutralizing Ab for 24h and determined CD68 expression by flow cytometry. Our results showed that LPS treated monocytes remained activated when co-cultured with podoplanin positive cells ( Figure 7D ). In contrast, podoplanin positive cells pre-treated with podoplanin neutralizing antibody could not interact well with activated monocytes, the inhibition of the interaction reduced the expression of CD68 ( Figure  7D ) on activated monocytes. Podoplanin positive cells did not express CD68 ( Figure 7A ). Furthermore, expression of selected cytokines and chemokines in the conditioned medium from podoplanin positive cells co-cultured with LPS activated monocytes with and without neutralizing antibody was assessed by quantitative ELISA. The cytokine and chemokine composition diverged accordingly with the two set ups of co-culture; pro-inflammatory IL-1α ( Figure 7E ) and IL12 ( Figure 7F ) were upregulated when monocytes bind podoplanin positive cells, on contrary, IL9 ( Figure 7G ) and IL10 ( Figure 7H ) were highly expressed in the presence of podoplanin neutralizing antibody. Our cytokine and chemokine analysis revealed a different pattern of inflammatory mediators in response to podoplanin positive cells binding to activated monocytes and a shift towards reparative monocyte/macrophage populations by the podoplanin neutralization.
In order to further investigate the activation and the phenotype of the monocytes/macrophages that either interact or not with podoplanin positive cells, we isolated podoplanin positive cells from a global GFP transgenic mouse (C57BL/6-Tg (UBC-GFP) 30Scha/J) (supplementary Figure  S5B and S5C), and co-cultured podoplanin positive cells with LPS activated monocytes isolated from the bone marrow of wild type C57BL/6J mice (in a ratio of 1:5; supplementary Figure S5A ). The two cell types were co-cultured with (supplementary Figure S5C ) and without (supplementary Figure S5B ) the presence of podoplanin neutralizing antibody. After 24h of coculture, the monocytes were separated from GFP-expressing podoplanin cells by magnetic beads columns (supplementary Figure S5A ). For this experiment we used GFP expressing podoplanin positive cells since it has been reported that activated monocytes can acquire podoplanin (28) , thus, we preferred to separate the two type of cells using GFP as a surface marker. After the magnetic cell separation the monocytes/macrophages were evaluated for the expression of major pro and anti-inflammatory cytokines transcripts by q-PCR (Supplementary Figure S5) . Our data showed that the mRNA levels of IL-1β (supplementary Figure S5D) and CD11b (supplementary Figure S5J) were reduced in the monocytes co-cultured in the presence of podoplanin neutralizing antibody. At the same time the mRNA level of reparative M2 macrophage lineage markers like ARG-1, CHI3I3 and CD163 were increased (supplementary Figure S5 F-H) . The mRNA expression of CD68 (supplementary Figure S5I) did not change within the groups, although we observed a reduction of the CD68 receptor by flow-cytometry analysis ( Figure 6D ). The IL-10 (supplementary Figure S5E ) mRNA level did not change between the groups although we observed significant increase of secreted IL-10 protein by ELISA assessment (Fig 7H) . This discrepancy between IL-10 mRNA and protein may likely reflect a relative short half-life of IL-10 mRNA (29), thus, the analysis of the secreted IL-10 protein is much more accurate.
To gain additional insights into podoplanin neutralization-mediated immunomodulation in vivo, we further investigated the pro and anti-inflammatory protein pattern to complement in vitro expression data. Expression analysis of selected chemokines was performed on tissue samples of mice hearts after MI to investigate differences of the inflammatory mediators in animals treated with podoplanin neutralizing antibody compared with untreated control group. In agreement with in vitro expression data, various cytokines were differentially expressed between the two groups; pro-inflammatory cytokines IL-1β and TNFα ( Figure 8A Figure 8K ) only in the treated group. The differences in cytokine and growth factor composition between treated and untreated animals suggested that podoplanin neutralization led to a favorable microenvironment more conducive to endogenous repair.
DISCUSSION
Exacerbated and prolonged inflammatory response is the leading cause of adverse remodeling after myocardial injury (30) . Targeted anti-inflammatory approaches were widely studied to reduce inflammation and improve cardiac repair (2); although, patients treated with highly selective strategies did not show a positive outcome after therapy (2) . The translational failure may be the result of exclusive inhibition of the recruitment of pro-inflammatory monocytes and decreased cytokine expression in the ischemic hearts (2) . The complete suppression of the inflammatory pathways interferes with the migration and activation of reparative and regenerative cells important for a positive tissue remodeling (2) . In this study, we investigated an alternative pathway involved in the modulation of inflammation after myocardial injury that has not been investigated before. We demonstrate that inhibition of the interaction between podoplanin expressing cells and podoplanin binding cells reduce but does not fully suppress the inflammation post MI and at the same time enhance an endogenous myocardial regeneration process after ischemic injury.
Podoplanin plays a pivotal role in the heart formation, is necessary for epicardial development and myocardial differentiation (22) . Podoplanin-null mice have increased embryonic lethality, impairment in development of the proepicardial organ, epicardial adhesion, and spreading and migration of epicardium-derived cells (22) . The epicardial pathology is correlated with reduced epithelial-mesenchymal transformation (EMT) caused by up-regulation of E-Cadherin, a protein normally downregulated by podoplanin (22) . In the adult heart, podoplanin at baseline is expressed only by lymphatic endothelial cells and importantly (15) , reappears in the infarcted murine hearts as early as 2 days after MI where it is widely expressed by a heterogeneous cohort of cells with a variable potency to adopt the lymphatic endothelial or mesenchymal fates (3). Why podoplanin re-appears in the heart only during the inflammatory phases is unknown. We demonstrated that podoplanin is a marker of injured myocardium; the fibrotic areas of hearts from animal treated with Angiotensin II are positive for podoplanin in immunostaining, moreover, we showed that podoplanin is expressed in the fibrotic tissue of ischemic human hearts. Similar to the ischemic heart, podoplanin is upregulated in human oral and mouse skin carcinomas where E-Cadherin is down-regulated by podoplanin, resulting in up-regulation of EMT leading to invasive growth and metastasis of the carcinoma cells (19) . Lately, has been shown that podoplanin increases in several different pathologies (9, 10).
Podoplanin binds its receptor CLEC-2, which is highly expressed by platelets and a variety of immune cells (4, 19) , thus, podoplanin is involved in the inflammation and may represent a key mediator of cross-talk between progenitor or mesenchymal resident cells and inflammatory cells recruited from the circulation at the site of injury. In concordance with a previous report, (3) we confirmed that podoplanin is not expressed in the heart by inflammatory cells, and resident podoplanin positive cells in the heart do not came from the circulation. It has been published that only 20% of podoplanin positive cells in the infarcted hearts expressed hematopoietic markers like F4/80, Ly6C and CD11b, thus the podoplanin expressing pools do not correspond to maturing macrophages since only a small population of circulating monocytes can acquire podoplanin during inflammation (7) . To address the role of podoplanin in the wound healing and scar structure, we blocked its activity using a neutralizing antibody as shown in the schematic cartoon (Supplementary Figure S6) . Since podoplanin knockout mice do not survive the embryonic phase, they do not represent an appropriate model for our study (22) . Therapeutic approaches using podoplanin neutralizing antibody have been shown to suppress tumor metastasis through antibody-dependent cellular cytotoxicity (31) or control of cellular invadopodia stability (32); podoplanin is, in fact, required for the complete maturation and stabilization of invadopodia (32) . In our model, we did not observe any differences in podoplanin expression in acute and chronic phases after MI between the treated and untreated groups; the treatment with the neutralizing antibody does not affect the cell migration or the cell composition in the scar, thus, podoplanin expressing cells resident in the heart displayed podoplanin under inflammatory condition and the neutralizing antibody was only able to interfere in the interaction of podoplanin with podoplanin binding cells. Similar observations were reported by other groups studying the biology of inflammation and possible selective targets in rheumatoid arthritis (11), psoriasis (10), sepsis (12) and deep vein thrombosis (13) .
Activation of inflammatory cascades in the infarcted heart stimulates a wide range of cellular responses (1) . During the granulation phase, neutrophils and monocytes clear the dead cells from wound and consequently anti-inflammatory stimuli promote repair enhancing the recruitment of progenitor cells involved in post MI angiogenesis and cardiac scar formation (30) . Based on the tissue damage, the pro-inflammatory signaling could be prolonged and accentuate adverse remodeling by activating proteases, transducing pro-apoptotic cascades in cardiomyocytes and promoting matrix degradation (26) . Our results showed that podoplanin neutralization reduced the scar size suggesting possible inhibition of the cell death during the inflammatory phase and supporting the repair during the proliferative and maturation phases. In fact, as early as 3 days after MI, animals treated with podoplanin neutralizing antibody displayed a reduced cell death probably due to the attenuated pro-inflammatory response. The massive cells death after ischemia results also in poorly vascularized scars; the consequent low blood flow inhibits the cell differentiation leading to superseding repair and fibrosis (33) . Mature scars of animals injected with podoplanin neutralizing antibody after MI showed an enhanced vascularization suggesting a potentially fertile microenvironment for progenitor cells differentiation. Moreover, during the proliferative phase, activation of endogenous fibrogenic signals stimulate and exacerbate ECM deposition in the ischemic area and alteration in the tissue structure and cardiac morphology results in severe left ventricle dysfunctions (26) . In our model, we observe an organized fibronectin deposition in structures similar to swirls, this type of structure is usually observed during new vessel formation. On the contrary, control animals show massive fibronectin assemblies along the ischemic area. Of note, podoplanin has been described to be important for the lymphatic vessel spreading and the new lymphangiogenesis is essential for the reduction of edema and fibrosis following MI (34) . Animals treated with neutralizing antibody do not express a reduction in new lymphangiogenesis at 30 days after MI suggesting that lymphatic endothelial cells do not represent an off target effect.
Cardiomyocyte regeneration after MI remains controversial and degree of regeneration remains hotly debated (35) . New myocyte rarely differentiate from circulating or resident progenitor cells (36) . Previous reports have suggested that healthy scar environment with pronounced neovascularization, reduced reactive oxygen species and correct alignment of the scar fibers may support the engraftment, proliferation and differentiation of progenitor cells (33) . Cardiac progenitor cells recruited to the injured heart are usually characterized by the expression of NKX 2.5, a myocyte transcription factor expressed at early stage of progenitor/stem cell differentiation and which represents an important marker for the myocyte fate (33) . Very interestingly, we observed NKX 2.5 positive cell assemblies in the ischemic area of animals treated with podoplanin neutralizing antibody on day 7 after MI; the pool of NKX 2.5 positive cells often co-expressed Troponin T. The presence of undifferentiated cells with myocyte lineage at early time point after injury correlated with the presence of bands of differentiated small myocyte in treated animals at 30 days after MI. In the absence of lineage tracing experiments we could not positively link small myocytes in the scar area as direct descendent of NKX2.5 positive progenitors, however, these data suggest that podoplanin neutralization may exert beneficial effects during the granulation and proliferation phases stimulating the recruitment and engraftment of putative NKX2.5 positive cardiac progenitors.
Targeting a select pathway during the inflammation that suppress injurious processes without interfering with the quality of reparative response is reflected not only on the size and geometry of the scar itself but also on the heart function (2). Animals treated with podoplanin neutralizing antibody perform a better contractility and the observed small myocytes islets resident in the scar tissue may contribute to the left ventricular function and contraction. The histological data, vis-a-vis the functional one, demonstrated that the neutralizing activity of podoplanin leads to the healthier tissue geometry organization in the treated animals compared to the scar formation in the control animals. Based on the sequential recruitment of inflammatory cells in the pro-inflammatory, proliferative and reparative phases after MI (27), we focused our attention on the monocyte populations as a priority over other described podoplanin-binding cells (21) . Co-culture of activated monocytes with podoplanin positive cells stimulated monocytes to produce pro-inflammatory cytokine, which are important for the recruitment of other immune cells, and that blocking of the interaction between the monocytes and podoplanin positive cells reduces the pro-inflammatory cytokine expression while simultaneously enhancing the expression of anti-inflammatory cytokines like IL-10 and reduced expression of CD68 positive cells. These observations open the possibility that therapeutic benefits of podoplanin neutralization may in part be dependent upon the inhibition of monocytes interaction with podoplanin positive cells leading to the upregulation of anti-inflammatory cytokines and to potentially a favorable microenvironment in the treated animals for the granulation phase and subsequent repair. Indeed, in vivo treatment with podoplanin neutralizing antibody, led to increased presence of reparative CD163 positive monocytes/macrophages. The total number of monocytes/macrophages (CD86 positive) recruited in the hearts at 3 days after MI was similar in both group of animals, but the percentage of cells double positive for CD86/CD206 monocytes/macrophages was much higher in the treated animals. Additionally, the cardiac expression of anti-inflammatory cytokine IL10 was also significantly elevated. It has been reported that IL-10 inhibits inflammation in the heart (37) and enhances myocardial repair and function after MI (37), specifically IL-10 attenuates the left ventricular dysfunction and remodeling with effects on fibrosis and capillary density (38, 39) . Interestingly, PDGFR-β and VEGF-A are upregulated in treated animals; these results may explain observed differences in angiogenesis that we observed in histological analysis.
One major finding of the present study is that podoplanin neutralization leads to a balance of pro-inflammatory and anti-inflammatory signals, this equilibrium may preserve the heart from exacerbated ischemic injury and stimulate a healthy scar formation. In the past decades several clinical trials using potent anti-inflammatory drugs or neutralizing antibodies for adhesion molecules, cytokines and chemokines have been used as a therapy for the MI, unfortunately none of them showed the expected outcomes (2). These studies suggested that dynamic alteration in cytokines and growth factors expression in the heart impaired the differentiation of several distinct sub-populations of macrophages in the inflammatory and reparative response (27) . Pro inflammatory cytokines are necessary for the recruitment of phagocytic cells in the inflammatory phase, but at the same time pro-reparative and pro-regenerative microenvironment is essential for the tissue survival and the inhibition of catastrophic myocardial remodeling (27) . Our findings on podoplanin neutralization may potentially open a new perspective in the post MI inflammatory balance and podoplanin interactome may potentially represent a novel target for cardio protective therapies.
METHODS
Animals and surgeries
Eight to ten-weeks-old male WT (C57BL/6J) and eight-to 8-to 10-weeks-old male global GFP (green fluorescent protein) (C57BL/6-Tg (UBC-GFP) 30Scha/J) were purchased from Jackson Research Laboratory (Bar Harbor, ME). Before treatments and at 7 and 30 days after myocardial infarction (MI) all animals were screened for baseline and post-MI echocardiography. MI was induced through left ventricular descending coronary artery (LAD) ligation as previously described (3). Following MI, animals were injected i.p. with 25μg of podoplanin neutralizing antibody (Santa Cruz, Sc-134483), 25μg of rabbit IgG control antibody (Cell Signaling Technologies, 2729S ) or 250μl of saline solution per animal at 1, 2, 7 and 15 days after MI. At 2, 3, 7 and 30 days after MI, animals were sacrificed under deep anesthesia, bilateral thoracotomy was performed, the hearts were removed and either fixed and processed for histological analysis, or enzymatically digested (40) for single-cell assessment by flowcytometry or cell culture purpose, as described below. Left ventricular hypertrophy and heart failure was induced in 8-to 10-week-old male WT (C57BL/6J) mice with Angiotensin II (1.6 mg/kg/day for 28 days) infusion using mini-osmotic pumps as described previously (41) . Twenty-eight days after treatment, mice were euthanized after final functional assessments and left ventricular tissue samples were collected for histology analysis.
Transthoracic echocardiographic analysis
Echocardiography was performed using the Vevo 2100 imaging system from VisualSonics, as published. Briefly, transthoracic two-dimensional echocardiography in mice anesthetized with 1-3% isoflurane was performed with the probe. M-mode echocardiography was carried out in the parasternal short axis in mice to assess heart rate (HR), left ventricular (LV) internal diameter in diastole (LVIDd) and systole (LVIDs), LV anterior and posterior wall in diastole and systole (LVAWd and LVAWs as well as LVPWd and LVAWs, respectively). LV fractional shortening (FS%) and ejection fraction (EF%) were calculated (42) .
In vivo hemodynamic measurements
In vivo cardiac hemodynamic was performed as described. Mice were anesthetized with a 2% Avertin and the right common carotid artery was isolated and cannulated with 1.4 French micromanometer (Millar Instruments, Houston, TX). LV pressure and heart rate (HR) were measured by this catheter advanced into the LV cavity, and data was recorded and analyzed on a PowerLab System (AD Instruments Pty Ltd., Mountain View, CA). These parameters as well as maximal values of the instantaneous first derivative of LV pressure (+dP/dtmax, as a measure of cardiac contractility) and minimum values of the instantaneous first derivative of LV pressure (-dP/dtmin, as a measure of cardiac relaxation) were recorded at baseline and after administration of the β-adrenergic receptor agonist, isoproterenol (0.1, 0.5, 1, 5, and 10 ng) (43) .
Human heart tissues samples
Heart tissue samples (n=5) were obtained from ischemic cardiomyopathy patients at the time of transplantation at the Temple University Cardiovascular Research Center and immediately frozen in liquid nitrogen and stored at -80°C until use. Tissue collection was conducted in accordance with the Declaration of Helsinki and approved by Temple University Institutional Review Board.
Immunohistochemistry of thin cardiac sections
Mouse hearts were washed with phosphate buffered saline and 10% formalin; fixed at least for 48h with 10% formalin and embedded in paraffin. Human heart tissue samples were fixed in 10% formalin and embedded in paraffin. Cardiac tissues were cut into 5-4 μm-thick sections. Following deparaffinization and rehydration mouse and human samples were stained with Masson Trichrome staining (Sigma-Aldrich, HT1079-1set and HT15-1kt), and after heatinduced antigen retrieval (pH 6.0), indirectly immunolabeled with commercially-available primary antibodies (Online Supplement, Table-S1 ) and corresponding fluorophore-conjugated secondary reagents (Online Supplement, Table-S1) or directly stained for the Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling (TUNEL) in red (Roche, 12156792910). Nuclei were counterstained with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich). Multiple sections from the hearts of at minimum 3 mice for each time point after MI were examined, and representative time points are described in the figures legend. Images were acquired with Niko Eclipse Ti fluorescence microscope using 4X, 10X, 20X, 40X, 60X and 100X objectives. Optical sections were projected into a single plane for each color channel and merged using Adobe Photoshop (Adobe) software. Quantitative image analysis was performed with NIH ImageJ by scoring multiple imaging fields.
Isolation and culture of podoplanin positive cells
WT and global GFP (green fluorescent protein) mice were euthanized at 2 days after induction of MI, as described above. The hearts were excised and extensively washed in phosphate buffered saline. The cardiac tissues were minced and subjected to repetitive rounds of enzymatic digestion with collagenase type 2 (Worthington Biochemical Corp., LS004176) until complete dissociation. Larger cells, such as mature myocytes, were precipitated, and the supernatants containing small cell populations were filtered through 40 µm cell strainers. For positive cell separation (magnetic column 130-042-401), the small cell population was incubated with podoplanin antibody (RnD System, BAF3244) previously bonded (over-night at 4 0 C) with magnetic beads (Anti-biotin MicroBeads, Miltenyi, 130-090-485) for 20 minutes at 4 0 C. After washing, the cells were cultured in expansion medium (EBM-2 medium from Lonza (CC-4176), supplemented with CC-4176 (Lonza) and ECGS (Bio-Rad 4110-5004, without antibiotics) on collagen coated flasks (Sigma-Aldrich, C8919). The purity of the isolation was analyzed by flow cytometry for podoplanin, LYVE-1 and CD68 on detached (0.2% trypsin) and fixed (4% PFA) cultured podoplanin positive cells.
Podoplanin neutralization activity
Podoplanin positive cells with and without podoplanin neutralizing antibody (5μg/ml of pAb antipodoplanin) were seeded on the inner side of transwell insets (Corning, 0.8 µm) and allowed to migrate from basal to apical side of transwell inserts in different conditions (with and without LPS) for 24h. Podoplanin positive cells migrated to the apical side were detached with 0.2% of trypsin and the absolute number of migrating cells was counted by flow cytometry.
Isolation and culture of monocytes
Bone marrow (BM) monocytes were isolated from BM mononuclear cells of mice fore and hindlimbs with density-gradient centrifugation as described previously (25) . Mononuclear cells were seeded on plastic dishes and the medium changed after 40 minutes. The monocyte population was cultured in DMEM with 20% FBS, 1% Penicillin Streptomycin solution and 20% of L929 conditioned medium. Monocytes were activated with 100ng/ml of LPS for 24h previous co-culture with podoplanin positive cells. Flow cytometry analysis of activated monocytes was performed on detached (TrypLE Express, Gibco, 12604-021) and fixed (4% PFA) cells for CD68, CD86, CD163 and CD206.
Isolation of peripheral blood mononuclear cells
Peripheral blood from control (sham operated) animals and animals at 1 and 2 days after MI, was collected in heparin loaded syringes after carotid artery incision under deep anesthesia. Single-cell suspension was fixed with 4% PFA and flow-cytometry analysis was performed for podoplanin and bone marrow lineage markers.
Co-culture of podoplanin positive cells and activated monocytes
Podoplanin positive cells were co-cultured for 24h with activated monocytes in the presence or absence of podoplanin neutralizing antibody (5μg/ml of pAb anti-podoplanin, RnD System, AF3244). Prior to co-culture, podoplanin positive cells were pre-treated with neutralizing antibody for 8h. Conditioned medium from podoplanin cells only, podoplanin cells treated with neutralizing antibody, podoplanin cells with activated monocytes and podoplanin cells pretreated with podoplanin neutralizing antibody and co-cultured with activated monocytes was analyzed by ELISA for the major pro-inflammatory and anti-inflammatory cytokines. Multiplex ELISA was performed by a third party (Evetechnologies, Canada: https://www.evetechnologies.com). After co-culture, podoplanin positive cells with activated monocytes and podoplanin cells pre-treated with podoplanin neutralizing antibody and cocultured with activated monocytes were detached with 0.2% of trypsin and scraper, and either fixed with 4% PFA and stained with CD68 and CD163 and analyzed by flow cytometry or separated for positive cell separation (magnetic column). The cells were incubated with anti GFP antibody (Invitrogen, A10259) previously bonded (over-night at 4 0 C) with magnetic beads (Anti-biotin MicroBeads, Miltenyi, 130-090-485) for 20 minutes at 4 0 C. After sorting the cells were lysed for the RNA extraction.
Enzyme linked immunosorbent assay (ELISA)
Mouse cytokine 32-plex discovery assay was performed by Eve Technologies (Eve Technologies, Calgary, Canada) (42) on cell culture supernatant of podoplanin cells only, podoplanin cells treated with neutralizing antibody, podoplanin cells with activated monocytes and podoplanin cells pre-treated with podoplanin neutralizing antibody and co-cultured with activated monocytes. Cytokines profile was measured using a 32-plex luminex-based platform and the analysis was performed on 3 different samples for each condition.
Quantitative real-time PCR
Expression levels of different genes were measured using quantitative real-time (RT) PCR technology. Total cellular RNA was isolated from mouse myocardial tissue at 3 days after MI of animals treated and untreated with podoplanin neutralizing antibody, or from monocytes separated from the podoplanin positive cells after co-culture with and without the presence of podoplanin neutralizing antibody using miRNeasy Mini Kit (Qiagen) following the manufacturer's instructions (44) . The cDNA was obtained from total RNA using the high capacity cDNA revere transcription kit (Applied Biosystems, 4368814). RT-PCR was performed on an Applied Biosystems 770 apparatus. The list of genes with the corresponding primers is shown in Table S2 in the online supplement material.
Flow-cytometry analysis of isolated and cultured cardiac cells
Infarcted WT mice treated and untreated (saline solution injected) with podoplanin neutralizing antibody were euthanized at 3 days after MI as described above. The hearts were excised and extensively washed in phosphate buffered saline. The cardiac tissues were minced and subjected to repetitive rounds of enzymatic digestion with collagenase type 2 (Worthington Biochemical Corp.) until complete dissociation. Larger cells, such as mature myocytes, were precipitated, and the supernatants containing small cell populations were filtered through 70 µm cell strainers. The small cell population was fixed with 4% PFA and stained for CD86, CD68, CD163 and CD206. Non-immune normal donkey and rat IgGs and isotype controls were employed as negative controls for the respective antigen-specific labeling. Samples were acquired with and analyzed using LSR-II flow cytometer. Single cells were gated using FSC-A/SSC-A followed by FSC-H/FSC-W and SSC-H/SSC-W in all experiments. Compensation settings, gating of positive populations and calculations of % positive cells were performed based on non-immune and isotype IgGs and fluorescence.
Statistical analysis
Statistical analysis was performed with the two-tailed t-test for single comparison within two groups or with one-way or two-way ANOVA test for multiple comparisons using GraphPad Prism (GraphPad Software). Data were expressed as mean ± SEM, Bonferroni post hoc test was used among all groups when applicable and a value of p<0.05 was considered as statistically significant.
Study approval
All animal experiments were conducted according to the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC) of Temple University. Human cardiac Tissue collection was conducted in accordance with the Declaration of Helsinki and approved by Temple University Institutional Review Board.
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